Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Gynecol Obstet Fertil Senol ; 49(12): 913-922, 2021 12.
Artigo em Francês | MEDLINE | ID: mdl-33639282

RESUMO

INTRODUCTION: The digestive involvement of endometriosis accounts for up to 20-25% of deep localisations. Precise mapping of digestive lesions is essential in order to plan surgery and specialized teams. The aim of this study is to assess the contribution of the MRI-coloscan couple in the preoperative assessment of digestive endometriosis. METHODS: We analyzed 45 files of patients referred for suspected digestive endometriosis. They had all undergone a preoperative MRI and coloscan associated with surgery throughout the year. We first compared the data collected in imaging, and then compared the synthesis of this data with the surgical procedure performed. RESULTS: 35 patients required digestive surgery. 24 of 45 files were concordant in MRI and coloscanner. Data from MRI alone matched with surgery in 69% of cases, against 84% for the coloscan. The synthesis allowed a concordance of 89%. 25 segmental resections, 2 discoid and 16 shaving were performed. The use of coloscan made up for nine extra cases: the detection of four additional cases of multifocality, a single undiagnosed case of a deep lesion, and allowed to specify the depth of the involvement in four cases. On the contrary, the MRI was correct compared to the CT in four cases. The presence of a digestive surgeon was necessary in 53% of cases. CONCLUSION: In the era of imaging staging, it would seem interesting to turn towards a subclassification of the digestive involvement of endometriosis in order to decide which surgery to perform. In our experience, the coloscan is a useful complement of MR, especially to assess the depth of involvement and the multifocality.


Assuntos
Procedimentos Cirúrgicos do Sistema Digestório , Endometriose , Laparoscopia , Cirurgiões , Procedimentos Cirúrgicos do Sistema Digestório/métodos , Endometriose/complicações , Endometriose/diagnóstico por imagem , Endometriose/cirurgia , Feminino , Humanos , Laparoscopia/métodos , Imageamento por Ressonância Magnética/métodos , Pelve/diagnóstico por imagem , Pelve/patologia
2.
J Gynecol Obstet Hum Reprod ; 46(8): 623-628, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28844663

RESUMO

OBJECTIVE: Three months after hysteroscopic sterilisation with Essure®, a confirmation test is required to evaluate the correct location of the inserts. The test may be conducted using a pelvic ultrasound (2D or 3D) or an abdominal X-ray. Should the location not look satisfactory on these tests, a follow-up hysterosalpingography (HSG) would be required. The objective of our study is to assess whether the Essure® 3-month confirmation test using a single X-ray or a combination of X-ray and ultrasound could reduce the use of HSG. STUDY DESIGN: This retrospective study examined patients who underwent birth control Essure® procedure between 2009 and 2015 in the Gynaecological Surgery Department at the Regional University Hospital Centre (CHRU) in Lille. We divided patients into two groups based on the imaging tests performed: single X-ray (2009-2010) versus X-ray and pelvic ultrasound (2014-2015). We then compared the results of the imaging tests and the use of HSG between the two groups. RESULTS: One hundred and thirty-four patients were tested, of which 60 (44.8%) using a single X-ray and 74 (55.2%) using a combination of X-ray and ultrasound. We note that the combined X-ray/ultrasound test reduces significantly the number of HSG performed (26.7% versus 12.2%, P=0.04). CONCLUSION: Compared to a single X-ray, the combination of X-ray and ultrasound enables to significantly limit the use of HSG.


Assuntos
Histeroscopia , Pelve/diagnóstico por imagem , Esterilização Tubária/instrumentação , Adulto , Feminino , Humanos , Histerossalpingografia , Imagem Multimodal , Radiografia , Estudos Retrospectivos , Ultrassonografia
3.
J Gynecol Obstet Biol Reprod (Paris) ; 43(6): 424-30, 2014 Jun.
Artigo em Francês | MEDLINE | ID: mdl-24440126

RESUMO

Esophageal atresia (EA) is a rare congenital malformation (1 in 2,500 to 3,500 births). Prenatal diagnosis (PN) is particularly interesting allowing search for associated malformations related to worse prognosis forms (reference ultrasound, MRI and amniocentesis) and planning the birth in an adapted medico-surgical center. Diagnosis of EA is usually suspected because of indirect and non-specific signs: association of polyhydramnios and absent or small stomach bubble. The visualization in ultrasound or MRI of cervical or thoracic fluid image corresponding to the expansion of the bottom of upper esophageal ("pouch sign") increases the specificity of diagnosis. However, prenatal diagnosis remains difficult and less than 50 % of EA are diagnosed prenatally. Biochemical analysis could improve these results. If EA is confirmed at birth, surgical management consists in a primary end-to-end anastomosis in first days of life, or in two-steps surgery if the defect is too large. Although current prognosis of EA is good, frequency of surgical complications and esophageal lesions secondary to gastroesophageal reflux justify a systematic and multidisciplinary extended follow-up.


Assuntos
Atresia Esofágica/diagnóstico , Doenças Fetais/diagnóstico , Diagnóstico Pré-Natal/métodos , Prognóstico , Atresia Esofágica/epidemiologia , Feminino , Doenças Fetais/epidemiologia , Humanos , Gravidez
5.
Ann Dermatol Venereol ; 130(3): 313-6, 2003 Mar.
Artigo em Francês | MEDLINE | ID: mdl-12746665

RESUMO

INTRODUCTION: Adult dermatomyositis is associated with cancer in 15 p. 100 to 50 p. 100 of cases and, hence, investigations should be systematically performed to search for cancer. A number of predictive factors have been reported. The aim of our study was to search for predictive factors of cancer, among adults with dermatomyositis. METHODS: We prospectively assessed 26 adults presenting with dermatomyositis, hospitalised in our department of dermatology from January 1993 to June 2000. The parameters assessed were: association with a cancer, age, gender, cutaneous necrosis, muscular weakness, electromyographic abnormalities, erythrocyte sedimentation rate, and muscular enzyme levels. RESULTS: Mean age was of 52 years and sex ratio (M/F) was of 0.53. Cancers were diagnosed in eight cases (31 p. 100) (mean age: 59.5 years; sex ratio=1; cancer localization: lung (2), breast (2), ovary, endometrium, bladder, and melanoma). Five patients in the cancer group had cutaneous necrosis and only 2 in the without cancer (p=0.01; PPV=71.4 p.100). Elevation of muscular enzyme was also associated with cancer. CONCLUSION: Our report demonstrates that cutaneous necrosis is closely associated with cancer and it suggests that in selected patients with dermatomyositis and cutaneous necrosis, more exhaustive and repeated investigations should be performed to search for cancer. The interest of elevation in muscular enzyme as a predictive factor of cancer is discussed.


Assuntos
Dermatomiosite/complicações , Dermatomiosite/patologia , Neoplasias/etiologia , Síndromes Paraneoplásicas/complicações , Síndromes Paraneoplásicas/patologia , Adulto , Fatores Etários , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Necrose , Neoplasias/patologia , Estudos Prospectivos , Medição de Risco , Fatores Sexuais
6.
Leukemia ; 15(11): 1706-12, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11681411

RESUMO

6-Mercaptopurine (6-MP) is metabolized by thiopurine S-methyltransferase (TPMT), an enzyme subject to genetic polymorphism. We investigated the relationships between the TPMT locus (TPMT activity and genotype) and the pharmacological response to 6-MP during maintenance therapy of 78 children with acute lymphoblastic leukemia (ALL). For each patient, 6-MP dosage, leukocyte counts and occurrence of infectious episodes were monitored on an 8 week basis. Higher 6-MP dosage was associated with higher TPMT activity (P = 0.03) and higher average leukocyte counts (P < 0.01). Eight patients (10%) carrying a TPMT mutant genotype (one homozygous and seven heterozygous) received lower 6-MP doses (average: 48 vs 65 mg/m2/day; P = 0.02) and had on average lower leukocyte counts (2834 vs 3398 cells/mm3; P = 0.003) than patients carrying the wild-type TPMT genotype. Higher occurrence of infectious episodes graded 2 or 3 was correlated with higher 6-MP dosage (P < 0.01) but no difference was observed between TPMT mutants and TPMT wild-type patients. Patients who received 6-MP dosage above the group median (62 mg/m2/day) or having a TPMT activity above the group median (21.5 nmol/h/ml) had a higher percentage of 8 week periods with infectious episodes requiring treatment (34% vs 17% and 33% vs 19%, respectively) than those with 6-MP dose or TPMT activity below the group median (P < 0.01). In the last 25 patients enrolled in the study, steady-state erythrocyte thioguanine nucleotide (TGN) concentrations were associated with lower leukocyte counts (P= 0.01) but not with a higher occurrence of infectious episodes. In contrast, higher steady-state erythrocyte methylmercaptopurine nucleotide (MeMPN) concentrations were associated with higher 6-MP dosage (P< 0.01) and higher occurrence of infectious episodes (P < 0.001). In conclusion, during maintenance therapy of ALL, children with higher TPMT activity receive a higher 6-MP dosage and may have infectious episodes caused by metabolism of 6-MP into methylmercaptopurine nucleotides.


Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Infecções/etiologia , Mercaptopurina/análogos & derivados , Mercaptopurina/efeitos adversos , Metiltransferases/fisiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Adolescente , Antimetabólitos Antineoplásicos/administração & dosagem , Antimetabólitos Antineoplásicos/farmacocinética , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Eritrócitos/metabolismo , Feminino , Genótipo , Humanos , Lactente , Contagem de Leucócitos , Masculino , Mercaptopurina/administração & dosagem , Mercaptopurina/metabolismo , Mercaptopurina/farmacocinética , Metiltransferases/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Tioguanina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA